Bharat Biotech Justifies Trial Site Shifts For Tetravalent Vaccine
Executive Summary
Trial-related challenges in India appear to have pushed vaccine maker Bharat Biotech towards opting for alternative sites for studies on its tetravalent vaccine. The firm says it has justified its position to the regulator, though some experts advise diligence in site selection.
You may also be interested in...
Bharat Biotech Gets WHO Nod For ‘Game-Changer’ Typhoid Vaccine
India’s Bharat Biotech has won WHO pre-qualification for a vaccine against typhoid fever that experts say will be a “game-changer” in preventing the bacterial disease, especially among children under two years - the age group most at risk.
Serum Leads Way With Heat-Stable Rotavirus Vaccine But Competition Unfazed
Serum Institute has launched a cut-price oral thermostable rotavirus vaccine in India, but competitors like Hilleman Labs, also developing a heat-stable vaccine in the area, aren’t losing much sleep, for now at least. Serum has also introduced a rabies monoclonal antibody.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.